These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 10753034)

  • 1. Nitric oxide and vascular responses in Type I diabetes.
    Chan NN; Vallance P; Colhoun HM
    Diabetologia; 2000 Feb; 43(2):137-47. PubMed ID: 10753034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelial nitric oxide in diabetes mellitus: too much or not enough?
    Farkas K; Sármán B; Jermendy G; Somogyi A
    Diabetes Nutr Metab; 2000 Oct; 13(5):287-97. PubMed ID: 11105972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of nitric oxide in insulin-dependent diabetes mellitus-related vascular complications.
    Traub O; Van Bibber R
    West J Med; 1995 May; 162(5):439-45. PubMed ID: 7785258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of nitric oxide in the development of diabetic angiopathy.
    Santilli F; Cipollone F; Mezzetti A; Chiarelli F
    Horm Metab Res; 2004 May; 36(5):319-35. PubMed ID: 15156413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelial dysfunction in diabetes mellitus.
    Cosentino F; Lüscher TF
    J Cardiovasc Pharmacol; 1998; 32 Suppl 3():S54-61. PubMed ID: 9883749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelial dysfunction, atherosclerosis and diabetes.
    Najemnik C; Sinzinger H; Kritz H
    Acta Med Austriaca; 1999; 26(5):148-53. PubMed ID: 11512191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic angiopathy: tracking down the culprits.
    Tooke JE; Shore AC; Cohen RA; Kluft C
    J Diabetes Complications; 1996; 10(3):173-81. PubMed ID: 8807468
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of C-peptide on microvascular blood flow and blood hemorheology.
    Forst T; Kunt T
    Exp Diabesity Res; 2004; 5(1):51-64. PubMed ID: 15198371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Von Willebrand factor in diabetic angiopathy.
    Kessler L; Wiesel ML; Attali P; Mossard JM; Cazenave JP; Pinget M
    Diabetes Metab; 1998 Sep; 24(4):327-36. PubMed ID: 9805643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus.
    Guerci B; Böhme P; Kearney-Schwartz A; Zannad F; Drouin P
    Diabetes Metab; 2001 Sep; 27(4 Pt 1):436-47. PubMed ID: 11547217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why does diabetes mellitus increase the risk of cardiovascular disease?
    Shahab A
    Acta Med Indones; 2006; 38(1):33-41. PubMed ID: 16479030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced glycation end products: sparking the development of diabetic vascular injury.
    Goldin A; Beckman JA; Schmidt AM; Creager MA
    Circulation; 2006 Aug; 114(6):597-605. PubMed ID: 16894049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes.
    Bucala R; Tracey KJ; Cerami A
    J Clin Invest; 1991 Feb; 87(2):432-8. PubMed ID: 1991829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired NO-dependent vasodilation in patients with Type II (non-insulin-dependent) diabetes mellitus is restored by acute administration of folate.
    van Etten RW; de Koning EJ; Verhaar MC; Gaillard CA; Rabelink TJ
    Diabetologia; 2002 Jul; 45(7):1004-10. PubMed ID: 12136399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Endothelial dysfunction and diabetes: possible role in kidney damage].
    Tesauro M; Leo R; Lauro R; Cardillo C
    G Ital Nefrol; 2009; 26 Suppl 46():62-70. PubMed ID: 19644821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
    Sorrentino SA; Bahlmann FH; Besler C; Müller M; Schulz S; Kirchhoff N; Doerries C; Horváth T; Limbourg A; Limbourg F; Fliser D; Haller H; Drexler H; Landmesser U
    Circulation; 2007 Jul; 116(2):163-73. PubMed ID: 17592079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study on the altered nitric oxide metabolism in experimental diabetes].
    Tábi T; Soltész Z; Magyar K; Szöko E
    Acta Pharm Hung; 2006; 76(1):19-23. PubMed ID: 17094672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Glucose metabolism in vascular endothelial cells].
    Yokota C; Okuda Y
    Nihon Rinsho; 2002 Jul; 60 Suppl 7():324-30. PubMed ID: 12238067
    [No Abstract]   [Full Text] [Related]  

  • 19. Diabetic mouse angiopathy is linked to progressive sympathetic receptor deletion coupled to an enhanced caveolin-1 expression.
    Bucci M; Roviezzo F; Brancaleone V; Lin MI; Di Lorenzo A; Cicala C; Pinto A; Sessa WC; Farneti S; Fiorucci S; Cirino G
    Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):721-6. PubMed ID: 14962949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitric oxide dynamics and endothelial dysfunction in type II model of genetic diabetes.
    Bitar MS; Wahid S; Mustafa S; Al-Saleh E; Dhaunsi GS; Al-Mulla F
    Eur J Pharmacol; 2005 Mar; 511(1):53-64. PubMed ID: 15777779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.